These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2168 related articles for article (PubMed ID: 25633049)

  • 21. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
    Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
    J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
    Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
    Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
    Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
    Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.
    Hoppe R; Fan P; Büttner F; Winter S; Tyagi AK; Cunliffe H; Jordan VC; Brauch H
    Oncotarget; 2016 Nov; 7(44):71235-71254. PubMed ID: 27659519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
    Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
    Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
    Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
    J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
    Xie X; Hu Y; Xu L; Fu Y; Tu J; Zhao H; Zhang S; Hong R; Gu X
    Tumour Biol; 2015 Sep; 36(9):7185-94. PubMed ID: 25894378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
    Muluhngwi P; Klinge CM
    Mol Cell Endocrinol; 2017 Nov; 456():76-86. PubMed ID: 28163101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 109.